Bone Biologics (BBLG) Non-Current Debt (2010 - 2019)

Bone Biologics (BBLG) has 10 years of Non-Current Debt data on file, last reported at $11.3 million in Q4 2019.

• Non-Current Debt for Q4 2019 came in at $11.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $11.3 million (changed N/A YoY), and the FY2019 annual result was $11.3 million, changed N/A from the prior year.
• Non-Current Debt advanced to $11.3 million in Q4 2019 per BBLG's latest filing, from $9.0 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $11.3 million in Q4 2019 and troughed at $3.8 million in Q1 2015.
• A 5-year average of $6.9 million and a median of $6.7 million in 2017 frame the typical range for Non-Current Debt.
• On a YoY basis, Non-Current Debt climbed as much as 48.8% in 2016 and fell as far as 7.16% in 2016.
• A 5-year view of Non-Current Debt shows it stood at $5.1 million in 2015, then soared by 48.8% to $7.6 million in 2016, then rose by 8.81% to $8.2 million in 2017, then advanced by 9.36% to $9.0 million in 2018, then grew by 25.78% to $11.3 million in 2019.
• Business Quant data shows BBLG's Non-Current Debt at $11.3 million in Q4 2019, $9.0 million in Q3 2018, and $8.6 million in Q2 2018.